drugset / Trial / NCT01537666
Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study is carried out to evaluate the safety, tolerability and pharmacokinetics of AeroVanc inhalation powder in healthy volunteers, and in patients with cystic fibrosis.
Timeline
- Start
- 2011-11
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vancomycin | Other / unclassified | 16 mg | Inhaled |
| Subject | Vancomycin | Other / unclassified | 32 mg | Inhaled |
| Subject | Vancomycin | Other / unclassified | 80 mg | Inhaled |
| Subject | Vancomycin | Other / unclassified | 250 mg | Inhaled |